Publications

Characterization of β-Lactam Resistance Mechanisms among Baseline Pseudomonas aeruginosa from 5 Ceftazidime-Avibactam Phase 3 Clinical Trials, Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #326

Regional Analysis of Resistance Phenotypes among Staphylococcus aureus Causing Infections in US Census Divisions: Telavancin Activity against Resistant Pathogens (2014-2016), Lead author: Duncan LR, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #333

Characterization of Enterobacter and Citrobacter spp. Isolates from United States Hospitals by Whole Genome Sequencing Analysis and Activity of Ceftazidime-Avibactam and Comparator Agents, Lead author: Castanheira M, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #320

Antimicrobial resistance among Gram-positive bacteria isolated in Latin American hospitals. by Sader HS, Moet GJ, Jones RN published in J Chemother 2009; 21 (6): 611-620

Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. by Sader HS, Fey PD, Fish DN, Limaye AP, Pankey G, Rahal J, Rybak MJ, Snydman DR, Steed LL, Waites K and Jones RN published in Antimicrob. Agents Chemother. 2009; 53 (10): 4127-4132

Resurgence of Pseudomonas endocarditis in Detroit, 2006-2008. by Reyes MP, Ali A, Mendes RE and Biedenbach DJ published in Medicine (Baltimore) 2009; 88 (5): 294-301

Strategic design of an effective β-lactamase inhibitor: LN-1-255, a 6-alkylidene-2′-substituted penicillin sulfone. by Pattanaik P, Bethel CR, Hujer AM, Hujer KM, Distler AM, Taracila M, Anderson VE, Fritsche TR, Jones RN, Pagadala SR, van den Akker F, Buynak JD and Bonomo RA published in J. Biol. Chem. 2009; 284 (2): 945-953

Antipseudomonal activity of piperacillin/tazobactam: More than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007). by Jones RN, Stilwell MG, Rhomberg PR and Sader HS published in Diagn. Microbiol. Infect. Dis. 2009; 65(3): 331-334

Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone resistance-determining regions. by Hirakata Y, Ohmori K, Mikuriya M, Saika T, Matsuzaki K, Hasegawa M, Hatta M, Yamamoto N, Kunishima H, Yano H, Kitagawa M, Arai K, Kawakami K, Kobayashi I, Jones RN, Kohno S, Yamaguchi K and Kaku M published in Antimicrob. Agents Chemother. 2009; 53 (10): 4225-4230

Antimicrobial susceptibility of Gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005-2008). by Gales AC, Sader HS, Ribeiro J, Zoccoli C, Barth A and Pignatari AC published in Braz J Infect Dis 2009; 13 (2): 90-98

Comparison of 2002-2006 OPTAMA programs for US hospitals: Focus on gram-negative resistance. by Crandon JL, Kuti JL, Jones RN and Nicolau DP published in Ann. Pharmacother. 2009; 43 (2): 220-227.

Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections. by Fritsche TR, Rhomberg PR, Sader HS and Jones RN. published in Antimicrob. Agents Chemother. 2008; 52 (3): 1187-1189

Treatment of severe infections in the era of high rates of antimicrobial resistance. by Sader HS and Gales AC published in Braz. J. Infect. Dis. 2008; 12 (Suppl 2): S1-S2

Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. by Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RN and Sorgel F, published in J Antimicrob Chemother 2007; 60 (5): 1038-1044

CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program. by Pfaller MA, Messer SA, Rhomberg PR and Castanheira M published in Int. J. Antimicrob. Agents 2017; 50 (3): 352-358

Determination of disk diffusion and MIC quality control guidelines for high dose cefepime-tazobactam (WCK 4282), a novel antibacterial combination consisting of a beta-lactamase inhibitor and a fourth-generation cephalosporin. by Riedel S, Huband MD, Sader HS, Flamm RK and Jones RN published in J. Clin. Microbiol. 2017; 55 (10): 3130-3134.

Monitoring antifungal resistance in a global collection of invasive yeasts and moulds: Application of CLSI epidemiological cutoff values and whole genome sequencing analysis for detection of azole resistance in Candida albicans. by Castanheira M, Deshpande LM, Davis AP, Rhomberg PR and Pfaller MA published in Antimicrob. Agents Chemother., 2017; 61 (10): e00906

ZAAPS Program results for 2015: An activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries. by Pfaller MA, Mendes RE, Streit JM, Hogan PA and Flamm RK published in J. Antimicrob. Chemother., 2017;72 (11): 3093-3099

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an antimicrobial surveillance program (2013-2015). by Pfaller MA, Shortridge D, Sader HS, Flamm RK and Castaneheira M published in J. Glob. Antimicrob. Resist. 2017: 10; 186-194

Telavancin activity in vitro tested against a worldwide collection of gram-positive clinical isolates (2014). by Duncan LR, Sader HS, Smart JI, Flamm RK and Mendes RE published in J. Glob. Antimicrob. Resist.2017; 10: 271-276

Activity of dalbavancin tested against gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014 – 2015). by Pfaller MA, Mendes RE, Sader HS, Castanheira M and Flamm RK published in J. Glob. Antimicrob. Resist. 2017; 11: 4-7

In vitro activity of telavancin against clinically important gram-positive pathogens from 69 U.S. medical centers (2015): Potency analysis by U.S. census divisions. by Pfaller MA, Sader HS, Flamm RK, Castanheira M, Smart JI and Mendes RE published in Microb. Drug Resist., 2017; 23 (6): 718-726

Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from US hospitals: Report from an antimicrobial surveillance program (PACTS, 2012-2015). by Shortridge D, Castanheira M, Pfaller MA and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61: e00465

Antimicrobial susceptibility trends among Staphylococcus aureus from United States hospitals: Results from 7 years of the ceftaroline (AWARE) surveillance program (2010-2016). by Sader HS, Mendes RE, Streit JM and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (9): e01043

Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and Echinocandin-resistant strains of Candida spp. by Pfaller MA, Messer SA, Rhomberg PR and Castanheira M published in Antimicrob. Agents Chemother. 2017; 61 (8): e00161

In vitro activity of linezolid against clinically important gram-positive cocci in the United States: A 5-year summary of in vitro activity and resistance mechanisms from the LEADER Surveillance Program (2011-2015). by Pfaller MA, Mendes RE, Streit JM, Hogan PA and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (7): e00609

Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV. by Mitton-Fry MJ, Brickner SJ, Hamel JC, Barham R, Brennan L, Casavant JM, Ding X, Finegan S, Hardink J, Hoang T, Huband MD, Maloney M, Marfat A, McCurdy SP, McLeod D, Subramanyam C, Plotkin M, Reilly U, Schafer J, Stone GG, Uccello DP, Wisialowski T, Yoon K, Zaniewski R and Zook C published in Bioorg. Med. Chem. Lett. 2017; 27 (15): 3353-3358

In vitro activity of delafloxacin and microbiological response against fluoroquinolone susceptible and non-susceptible S. aureus isolates from two Phase 3 Studies of acute bacterial skin and skin structure infections (ABSSSI). by McCurdy S, Lawrence L, Quintas M, Woosley L, Flamm R, Tseng C and Cammarata S published in Antimicrob. Agents Chemother. 2017; 61 (9): e007722017

Gepotidacin (GSK2140944) in vitro activity against Gram-positive and Gram-negative bacteria. by Flamm RK, Farrell DJ, Rhomberg PR, Scangarella-Oman NE and Sader HS published in Antimicrob. Agents Chemother. 2017; 61 (7): e00468-17

Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. by Castanheira M, Huband MD, Mendes RE and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (9): e00567

In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary ABSSSI Isolates from the United States (2014-2016): Results from the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-4

In Vitro Activity of Telavancin against Staphylococcus aureus Causing Pneumonia or Skin and Skin Structure Infections with Concomitant Bloodstream Infections in United States Hospitals (2012-2016). Lead author: L Duncan, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-141

Antimicrobial Synergistic Effect of a New Anti-Gram-Positive Agent Tested in Combination with a Polymyxin Derivative against Gram-Negative Pathogens, Including ESKAPE Group Organisms. Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-23

In Vitro Activity of Plazomicin and Comparator Agents against Urinary Tract Infection Isolates from the United States and Europe. Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-10

Emergence of Proteeae Species Isolates Carrying bla_IMP-27-like in United States and Mexico. Lead author: L Deshpande, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Sunday-125

Intrinsic Resistance Mechanisms Detected Among Ceftazidime-Avibactam-Susceptible and -Resistant Pseudomonas aeruginosa Isolates Collected from United States Hospitals (2015). Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA.
#Sunday-166

Antimicrobial Activity of Ceftobiprole When Tested against Isolates from Diabetic Foot Infections (2013-2016). Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-6

Aminoglycoside-Resistance Genes Among 2014-2015 US Carbapenem-Resistant Enterobacteriaceae Isolates and Activity of Plazomicin against Characterized Isolates. Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-9

Antimicrobial Susceptibility Trends among Staphylococcus aureus from US Hospitals: Results from 7 years of the Ceftaroline (AWARE) Surveillance Program (2009-2015). Lead author: H Sader presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-142

Activity of Solithromycin and Comparators against Respiratory Tract Pathogens Collected in the 2016 Global SENTRY Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-7

Antimicrobial Activity of Ceftobiprole When Tested against Contemporary Isolates from US Medical Centers (2016). Lead author: R Flamm, presented at ASM Microbe 2017, New Orleans, Louisiana, USA
# Sunday-12

Updated Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bloodstream Infections in United States and European Hospitals (2014-2016). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-33

Potentiation of Clarithromycin When Combined with a New Cationic Peptide against Gram-negative Clinical Isolates and Molecular Analysis of Macrolide Resistance Mechanisms by Next-Generation Sequencing. Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-162

Synergistic Effect of Novel Gyrase Inhibitor Agents (SPR750 and SPR751) in Combination with a Polymyxin Derivative (SPR741) against Recent Acinetobacter baumannii and Enterobacteriaceae. Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-13

In vitro Antibacterial Activity of Omadacycline and Comparators against Key Respiratory, Skin and Skin Structure, and Urinary Tract Pathogens Collected from the United States and Europe during the 2016 SENTRY Antimicrobial Surveillance Program. Lead author: M Huband presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-45

Multilaboratory Broth Microdilution MIC Reproducibility Study for GSK3342830, a Novel Catechol-Cephem. Lead author: P Rhomberg, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-287

Global Surveillance: Susceptibility of Ceftolozane-Tazobactam against Pseudomonas aeruginosa, Klebsiella spp., and Escherichia coli Isolates Collected in Asia-Pacific, North and Latin America, and Europe from 2011-2016. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-29

Antimicrobial Activity of Meropenem-WCK 4234 (WCK 5999) against Clinical Isolates of Acinetobacter spp. Collected Worldwide and Stratified by Infection Type. Lead author: H Sader, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Saturday-97

Fosfomycin In Vitro Activity against Bacteria with Various Mechanisms of Resistance to Other Antibacterials from US Hospitals. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-61

Evaluation of Fosfomycin Activity When Combined with Selected Antimicrobial Agents and Tested against Bacterial Isolates Using Checkerboard Methods. Lead author: P Rhomberg, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-406